Evidence map›Paper›PMID 35987188›Full record

ArticleBioorganic chemistry2022

Syntheses and studies of deuterated Imdiazo[1,2-a]pyridine-3-carboxamides with potent anti-tuberculosis activity and improved metabolic properties.

Rui Liu, Kate Marshall, Rui Ma, Kim Lien Thi Pham, Gauri Shetye, Zhihao Liu, Sanghyun Cho, Hyunyoung Jeong, Scott G Franzblau, Garrett C Moraski and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Rui LiuDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Kate MarshallDepartment of Chemistry and Biochemistry, Montana State University, 103 Chemistry and Biochemistry, Bozeman, Montana 59717, USA.
Rui MaInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA.
Kim Lien Thi PhamInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA.
Gauri ShetyeInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA.
Zhihao LiuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA.
Sanghyun ChoInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA.
Hyunyoung JeongDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA.
Scott G FranzblauInstitute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA.
Garrett C MoraskiDepartment of Chemistry and Biochemistry, Montana State University, 103 Chemistry and Biochemistry, Bozeman, Montana 59717, USA. Electronic address: garrett.moraski@montana.edu.
Marvin J MillerDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA. Electronic address: mmiller1@nd.edu.
University of Illinois Chicago · USMontana State University · USUniversity of Notre Dame · US

Funding

Design, Syntheses and Studies of Novel Antituberculosis AgentsR37AI054193 · NIAID · UNIVERSITY OF NOTRE DAME · PI MILLER, MARVIN J · 2016 to 2025
$5.2M
NIAID NIH HHS R37 AI054193
6 · The paper itself

Abstract

The imidazo[1,2-a]pyridine-3-carboxyamides (IAPs) are a unique class of compounds endowed with impressive nanomolar in vitro potency against Mycobacterium tuberculosis (Mtb) as exemplified by clinical candidate Telacebec (Q203). These compounds target mycobacterial respiration through inhibition of the QcrB subunit of cytochrome bc1:aa

Indexed as

Mycobacterium tuberculosisTuberculosisAnimalsAntitubercular AgentsHumansMicePyridinesAntitubercular AgentsPyridinesAnti-tuberculosisDeuterated imidazopyridinesMetabolismMycobacterial respiration inhibition

Identifiers

PMID35987188
PMCPMC10262914
OpenAlexW4290830114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.